Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 22 | 2021 | 1275 | 1.380 |
Why?
|
| HIV Infections | 38 | 2021 | 4946 | 1.310 |
Why?
|
| Tuberculosis | 11 | 2021 | 530 | 1.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 16 | 2018 | 468 | 0.910 |
Why?
|
| Drug Resistance, Viral | 11 | 2020 | 268 | 0.780 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2018 | 7 | 0.750 |
Why?
|
| HIV-1 | 14 | 2021 | 1239 | 0.660 |
Why?
|
| Antitubercular Agents | 7 | 2021 | 299 | 0.630 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2018 | 113 | 0.630 |
Why?
|
| Male | 39 | 2021 | 6489 | 0.620 |
Why?
|
| Adult | 37 | 2021 | 5664 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 8 | 2018 | 542 | 0.610 |
Why?
|
| Coinfection | 6 | 2021 | 268 | 0.600 |
Why?
|
| Viral Load | 14 | 2020 | 808 | 0.550 |
Why?
|
| Female | 39 | 2021 | 8751 | 0.540 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 27 | 0.450 |
Why?
|
| Humans | 42 | 2021 | 14077 | 0.450 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 51 | 0.440 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 59 | 0.430 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 44 | 0.430 |
Why?
|
| Organophosphonates | 4 | 2013 | 45 | 0.420 |
Why?
|
| Hepatitis B virus | 2 | 2013 | 155 | 0.410 |
Why?
|
| Adenine | 4 | 2013 | 88 | 0.410 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2016 | 326 | 0.360 |
Why?
|
| Medication Adherence | 3 | 2020 | 137 | 0.360 |
Why?
|
| CD4 Lymphocyte Count | 14 | 2018 | 654 | 0.350 |
Why?
|
| Benzoxazines | 5 | 2014 | 119 | 0.330 |
Why?
|
| Treatment Outcome | 13 | 2018 | 867 | 0.310 |
Why?
|
| South Africa | 22 | 2021 | 7312 | 0.310 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2018 | 320 | 0.290 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2016 | 145 | 0.280 |
Why?
|
| Middle Aged | 16 | 2021 | 3425 | 0.280 |
Why?
|
| Patient Compliance | 3 | 2016 | 120 | 0.270 |
Why?
|
| Bacteremia | 2 | 2018 | 79 | 0.270 |
Why?
|
| Salvage Therapy | 2 | 2018 | 6 | 0.260 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2011 | 194 | 0.260 |
Why?
|
| Rifampin | 4 | 2021 | 189 | 0.260 |
Why?
|
| HIV Protease Inhibitors | 2 | 2021 | 92 | 0.240 |
Why?
|
| Drug Substitution | 2 | 2016 | 29 | 0.230 |
Why?
|
| Cohort Studies | 11 | 2016 | 939 | 0.230 |
Why?
|
| Retrospective Studies | 4 | 2021 | 767 | 0.220 |
Why?
|
| Receptors, CCR5 | 2 | 2021 | 54 | 0.210 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2014 | 33 | 0.210 |
Why?
|
| Disease Resistance | 1 | 2021 | 6 | 0.200 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 59 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 12 | 0.190 |
Why?
|
| Nontuberculous Mycobacteria | 2 | 2018 | 4 | 0.190 |
Why?
|
| Viremia | 1 | 2020 | 66 | 0.180 |
Why?
|
| Treatment Failure | 6 | 2018 | 175 | 0.170 |
Why?
|
| Africa South of the Sahara | 6 | 2020 | 328 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2018 | 1131 | 0.170 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 271 | 0.170 |
Why?
|
| HIV | 3 | 2021 | 380 | 0.160 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 2 | 0.160 |
Why?
|
| Lamivudine | 3 | 2013 | 86 | 0.150 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 22 | 0.150 |
Why?
|
| Cytokines | 2 | 2016 | 107 | 0.150 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 31 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 40 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2016 | 3 | 0.130 |
Why?
|
| DNA, Viral | 2 | 2013 | 165 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 274 | 0.130 |
Why?
|
| Aged | 6 | 2018 | 1650 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 136 | 0.130 |
Why?
|
| Pyrazinamide | 1 | 2015 | 14 | 0.120 |
Why?
|
| Stavudine | 2 | 2012 | 78 | 0.120 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 20 | 0.120 |
Why?
|
| Ritonavir | 3 | 2021 | 137 | 0.120 |
Why?
|
| Alkynes | 5 | 2014 | 113 | 0.120 |
Why?
|
| Cyclopropanes | 5 | 2014 | 119 | 0.120 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 20 | 0.120 |
Why?
|
| Cyclohexanes | 2 | 2014 | 5 | 0.120 |
Why?
|
| Triazoles | 2 | 2014 | 15 | 0.120 |
Why?
|
| Young Adult | 6 | 2018 | 2357 | 0.120 |
Why?
|
| Transcriptome | 1 | 2014 | 11 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 47 | 0.110 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 153 | 0.110 |
Why?
|
| Hepatitis B e Antigens | 1 | 2013 | 26 | 0.110 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2013 | 6 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 8 | 0.110 |
Why?
|
| Phylogeny | 1 | 2013 | 231 | 0.110 |
Why?
|
| Adolescent | 6 | 2018 | 2858 | 0.100 |
Why?
|
| Adipocytes | 1 | 2012 | 23 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1149 | 0.100 |
Why?
|
| Nevirapine | 1 | 2013 | 146 | 0.100 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2015 | 210 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2013 | 123 | 0.100 |
Why?
|
| Tenofovir | 4 | 2013 | 158 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 7 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 50 | 0.100 |
Why?
|
| Kidney | 1 | 2011 | 46 | 0.100 |
Why?
|
| RNA, Viral | 4 | 2012 | 303 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2018 | 149 | 0.090 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2010 | 5 | 0.090 |
Why?
|
| AIDS Dementia Complex | 1 | 2010 | 29 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2010 | 55 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2010 | 35 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2013 | 467 | 0.080 |
Why?
|
| Mutation | 3 | 2018 | 299 | 0.080 |
Why?
|
| Time Factors | 3 | 2016 | 503 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 243 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 163 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 449 | 0.070 |
Why?
|
| Lopinavir | 2 | 2021 | 137 | 0.070 |
Why?
|
| Zambia | 2 | 2018 | 112 | 0.070 |
Why?
|
| Nelfinavir | 1 | 2004 | 6 | 0.060 |
Why?
|
| Organophosphates | 1 | 2004 | 8 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2004 | 10 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 41 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2012 | 65 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 380 | 0.050 |
Why?
|
| Rifabutin | 1 | 2021 | 4 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 263 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2021 | 94 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 78 | 0.050 |
Why?
|
| Zidovudine | 2 | 2010 | 59 | 0.040 |
Why?
|
| Africa | 2 | 2011 | 360 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 392 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 55 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 37 | 0.040 |
Why?
|
| Public Sector | 1 | 2018 | 82 | 0.040 |
Why?
|
| Public Health | 1 | 2018 | 122 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 1377 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 1 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 5 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 22 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 72 | 0.030 |
Why?
|
| Ethambutol | 1 | 2015 | 9 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tanzania | 1 | 2015 | 84 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2014 | 5 | 0.030 |
Why?
|
| Isoniazid | 1 | 2015 | 110 | 0.030 |
Why?
|
| Sputum | 1 | 2015 | 135 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 224 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 34 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 60 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 364 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 11 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Plasma | 1 | 2013 | 39 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 30 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 125 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 96 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 19 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 31 | 0.030 |
Why?
|
| Glucose | 1 | 2012 | 45 | 0.030 |
Why?
|
| Body Weight | 1 | 2013 | 110 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 124 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 44 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 17 | 0.030 |
Why?
|
| Inflammation | 1 | 2012 | 103 | 0.020 |
Why?
|
| Lost to Follow-Up | 1 | 2012 | 62 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 263 | 0.020 |
Why?
|
| World Health Organization | 1 | 2012 | 134 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 103 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 180 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 65 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 51 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 322 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 252 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 325 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Didanosine | 1 | 2010 | 11 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 30 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 9 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 41 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 55 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 430 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 107 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 230 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 25 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1410 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 197 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1815 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 312 | 0.020 |
Why?
|
| Risk Factors | 1 | 2011 | 1431 | 0.020 |
Why?
|
| Furans | 1 | 2004 | 4 | 0.020 |
Why?
|
| Carbamates | 1 | 2004 | 12 | 0.010 |
Why?
|